NYSE:TEVAPharmaceuticals
Teva Pharmaceutical (TEVA) Q1 EPS Of US$0.32 Tests Bullish Profitability Narrative
Teva Pharmaceutical Industries (TEVA) opened 2026 with Q1 revenue of US$3.98b and basic EPS of US$0.32, setting the tone for how its earnings story is evolving after a period marked by large one off items. Over recent quarters the company has seen revenue move from US$3.89b in Q1 2025 to US$4.71b in Q4 2025 before landing at US$3.98b in Q1 2026. Basic EPS moved from US$0.19 to US$0.42 and then to US$0.32 over the same stretch, giving you a clear view of how profitability per share has tracked...